A Phase 3 interventional study of BGB-3111 and Ibrutinib in Waldenström's Macroglobulinemia, sponsored by BeiGene. Completed at 58 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.
Sponsored by BeiGene · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing ibrutinib in Waldenstrom Macroglobulinemia — 2 open to participants now, 7 under way, 2 of them phase 3. ibrutinib · Waldenstrom Macroglobulinemia.
Among the 25 studies testing ibrutinib in Waldenstrom Macroglobulinemia, this one is the 2nd largest by enrollment, is one of 2 that started in 2017, is one of 4 in phase 3, and was the 13th registered.
524 studies on the registry are indexed under Waldenstrom Macroglobulinemia; 61 are open to participants now.
Browse Waldenstrom Macroglobulinemia studies →2 of the 25 studies testing ibrutinib in Waldenstrom Macroglobulinemia are open now, in 1 country. Recruiting first, the newest first:
University College, London · Sites in United Kingdom
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China
Ages 18–75
By country, each count listing its studies:
ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 47 Waldenstrom Macroglobulinemia studies recruiting now, 43 (91%) set no upper age limit and 1 (2%) stops at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 5 · Phase 4 1
First in 2009; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 201 is above the median of 39 across 429 interventional studies indexed under Waldenstrom Macroglobulinemia.
Median enrollment 48 across the 25 interventional studies. Of the 15 that completed or were terminated, 10 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 25 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
10 studies in Waldenstrom Macroglobulinemia by BeOne Medicines: 3 open now, 5 under way, none of them phase 3. Of 4 finished, 2 (50%) have results posted.
Among the 10 studies in Waldenstrom Macroglobulinemia by BeOne Medicines, this one is one of 2 that started in 2017, is the only one in phase 3, and was the 1st registered.
BeOne Medicines’s Waldenstrom Macroglobulinemia studies by the year they started, since 2017.
2 of the studies testing ibrutinib in Waldenstrom Macroglobulinemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT01479842Kami Maddocks, MDRituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | 2026-12-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 25 studies testing ibrutinib in Waldenstrom Macroglobulinemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among BeOne Medicines’s 10 in Waldenstrom Macroglobulinemia:
This tab as a report to print or save as PDF → With an account.
This study evaluated the safety, efficacy and clinical benefit of BGB-3111 (zanubrutinib) vs ibrutinib in participants with MYD88 Mutation Waldenström's Macroglobulinemia.
This open-label, randomized study compared the efficacy and safety of the Bruton's Tyrosine Kinase (BTK) inhibitors BGB-3111 and ibrutinib in participants with Waldenström's Macroglobulinemia who require therapy. Participants had baseline bone marrow samples assayed for sequencing of the MYD88 gene. 201 participants with the MYD88 mutation were enrolled and randomized to receive 160 mg BGB-3111 orally twice per day (PO BID) (treatment Arm A) or to receive 420mg ibrutinib orally once per day (PO QD) (treatment Arm B) until disease progression or unacceptable toxicity.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with the MYD88 mutation received Ibrutinib
Drug: Ibrutinib
Participants with the MYD88 mutation received zanubrutinib
Drug: BGB-3111
160 mg PO BID until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
Also known as: Zanubrutinib, Brukinsa
420 mg PO QD until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
Also known as: IMBRUVICA
Percentage of Participants Achieving Either a Complete Response (CR) or Very Good Partial Response (VGPR) Using an Adaptation of the Response Criteria Updated at the Sixth International Workshop on WM as Assessed by an Independent Review Committee (IRC)
Percentage of participants with CR, defined as normal serum immunoglobulin M (IgM) levels, disappearance of monoclonal protein by immunofixation, and negative cryoglobulinemia if cryoglobulinemia was positive at baseline, or VGPR, defined as ≥90% reduction in serum IgM level from baseline or normal serum IgM values.
Time frame: Up to approximately 2 years and 7 months
Percentage of Participants Achieving Major Response Rate (MRR) as Assessed by IRC
MRR defined as the percentage of participants achieving a best response of response of CR, defined as normal serum IgM levels, disappearance of monoclonal protein by immunofixation, and negative cryoglobulinemia if cryoglobulinemia was positive at baseline, VGPR, defined as ≥90% reduction in serum IgM level from baseline or normal serum IgM values or partial response (PR) defined as ≥50% reduction of serum IgM from baseline.
Time frame: Up to approximately 2 years and 7 months
Duration of Response (DOR) as Assessed by IRC
DOR defined as the time from first determination of response (CR, VGPR or PR) until first documentation of progression or death, whichever comes first. CR is defined as normal serum IgM levels, disappearance of monoclonal protein by immunofixation, and negative cryoglobulinemia if cryoglobulinemia was positive at baseline, VGPR, is defined as ≥90% reduction in serum IgM level from baseline or normal serum IgM values or partial response (PR) is defined as ≥50% reduction of serum IgM from baseline.
Time frame: Up to approximately 2 years and 7 months
DOR as Assessed by IRC: Event -Free Rate
Estimated percentage of participants who were event-free based on Kaplan-Meier method.
Time frame: 12 and 18 months from the date of randomization (up to approximately 2 years and 7 months)
Percentage of Participants Achieving Either CR or VGPR in as Assessed by the Investigator
Percentage of participants with CR, defined as normal serum IgM levels, disappearance of monoclonal protein by immunofixation, and negative cryoglobulinemia if cryoglobulinemia was positive at Baseline, or VGPR, defined as ≥90% reduction in serum IgM level from baseline or normal serum IgM values.
Time frame: Up to approximately 5 years and 5 months
DOR as Assessed by the Investigator
DOR is defined as the time from first determination of response (CR, VGPR or PR) until first documentation of progression or death, whichever comes first
Time frame: Up to approximately 5 years and 5 months
DOR as Assessed by the Investigator: Event-Free Rate
Estimated percentage of participants who were event-free based on Kaplan-Meier method.
Time frame: 24,36 and 48 months from the date of randomization (up to approximately 5 years and 5 months)
Progression Free Survival (PFS) as Assessed by the IRC
PFS as assessed by the IRC, defined as time from randomization to the first documentation of progression (per modified International Workshop on Waldenström macroglobulinemia \[IWWM criteria\]) or death, whichever occurs first
Time frame: Up to approximately 2 years and 7 months
PFS as Assessed by IRC: Event-Free Rate
Estimated percentage of participants who were event-free based on Kaplan-Meier method
Time frame: 12 and 18 months from the date of randomization (up to approximately 2 years and 7 months)
PFS as Assessed by the Investigator
PFS as assessed by the Investigator, defined as time from randomization to the first documentation of progression (per modified IWWM criteria) or death, whichever occurs first.
Time frame: Up to approximately 5 years and 5 months
PFS as Assessed by the Investigator: Event-Free Rate
Percentage of participants who were event-free based on Kaplan-Meier method.
Time frame: 24,36 and 48 months from the date of randomization (up to approximately 5 years and 5 months)
Percentage of Participants With Resolution of All Treatment-precipitating Symptoms
Time frame: Up to approximately 5 years and 5 months
Percentage of Participants With an Anti-Lymphoma Effect
Anti-Lymphoma Effect is defined as any reduction in bone marrow involvement by lymphoplasmacytoid lymphocytes and/or size of lymphadenopathy and/or splenomegaly by CT scan, at any time during the course of study treatment.
Time frame: Up to approximately 5 years and 5 months
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: Up to approximately 5 years and 5 months
A total of 201 participants were randomized to Arm A and Arm B in 12 countries in Australia, Europe, United Kingdom and United States.
| Milestone | Arm A: Ibrutinib | Arm B: Zanubrutinib |
|---|---|---|
| Started | 99 | 102 |
| Completed | 0 | 0 |
| Not completed | 99 | 102 |
| Withdrew: Sponsor's decision to end the study | 20 | 13 |
| Withdrew: Death | 18 | 14 |
| Withdrew: Withdrawal by subject | 9 | 8 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Enrolled in long-term extension study | 48 | 66 |
| Withdrew: Physician decision | 2 | 1 |
| Withdrew: Participant randomized but died before dosing | 1 | 0 |
Percentage of participants with CR, defined as normal serum immunoglobulin M (IgM) levels, disappearance of monoclonal protein by immunofixation, and negative cryoglobulinemia if cryoglobulinemia was positive at baseline, or VGPR, defined as ≥90% reduction in serum IgM level from baseline or normal serum IgM values.
| Percentage of Participants | Arm A: Ibrutinib | Arm B: Zanubrutinib |
|---|---|---|
| Percentage of Participants Achieving Either a Complete Response (CR) or Very Good Partial Response (VGPR) Using an Adaptation of the Response Criteria Updated at the Sixth International Workshop on WM as Assessed by an Independent Review Committee (IRC) | 19.2 (12.0 to 28.3) | 28.4 (19.9 to 38.2) |
MRR defined as the percentage of participants achieving a best response of response of CR, defined as normal serum IgM levels, disappearance of monoclonal protein by immunofixation, and negative cryoglobulinemia if cryoglobulinemia was positive at baseline, VGPR, defined as ≥90% reduction in serum IgM level from baseline or normal serum IgM values or partial response (PR) defined as ≥50% reduction of serum IgM from baseline.
| Percentage of Participants | Arm A: Ibrutinib | Arm B: Zanubrutinib |
|---|---|---|
| Percentage of Participants Achieving Major Response Rate (MRR) as Assessed by IRC | 77.8 (68.3 to 85.5) | 77.5 (68.1 to 85.1) |
DOR defined as the time from first determination of response (CR, VGPR or PR) until first documentation of progression or death, whichever comes first. CR is defined as normal serum IgM levels, disappearance of monoclonal protein by immunofixation, and negative cryoglobulinemia if cryoglobulinemia was positive at baseline, VGPR, is defined as ≥90% reduction in serum IgM level from baseline or normal serum IgM values or partial response (PR) is defined as ≥50% reduction of serum IgM from baseline.
| Months | Arm A: Ibrutinib | Arm B: Zanubrutinib |
|---|---|---|
| Duration of Response (DOR) as Assessed by IRC | NA (8.0 to NA) | NA (NA to NA) |
Estimated percentage of participants who were event-free based on Kaplan-Meier method.
| Percentage of Participants | Arm A: Ibrutinib | Arm B: Zanubrutinib |
|---|---|---|
| 12 Months | 87.9 (77.0 to 93.8) | 94.4 (85.8 to 97.9) |
| 18 Months | 87.9 (77.0 to 93.8) | 85.2 (71.7 to 92.6) |
Percentage of participants with CR, defined as normal serum IgM levels, disappearance of monoclonal protein by immunofixation, and negative cryoglobulinemia if cryoglobulinemia was positive at Baseline, or VGPR, defined as ≥90% reduction in serum IgM level from baseline or normal serum IgM values.
| Percentage of Participants | Arm A: Ibrutinib | Arm B: Zanubrutinib |
|---|---|---|
| Percentage of Participants Achieving Either CR or VGPR in as Assessed by the Investigator | 25.3 (17.1 to 35.0) | 38.2 (28.8 to 48.4) |
DOR is defined as the time from first determination of response (CR, VGPR or PR) until first documentation of progression or death, whichever comes first
| Months | Arm A: Ibrutinib | Arm B: Zanubrutinib |
|---|---|---|
| DOR as Assessed by the Investigator | NA (53.5 to NA) | NA (NA to NA) |
Estimated percentage of participants who were event-free based on Kaplan-Meier method.
| Percentage of Participants | Arm A: Ibrutinib | Arm B: Zanubrutinib |
|---|---|---|
| 24 Months | 87.7 (77.8 to 93.4) | 89.7 (80.4 to 94.7) |
| 36 Months | 77.5 (65.9 to 85.6) | 81.1 (70.1 to 88.4) |
| 48 Months | 73.9 (61.6 to 82.8) | 81.1 (70.1 to 88.4) |
PFS as assessed by the IRC, defined as time from randomization to the first documentation of progression (per modified International Workshop on Waldenström macroglobulinemia \[IWWM criteria\]) or death, whichever occurs first
| Months | Arm A: Ibrutinib | Arm B: Zanubrutinib |
|---|---|---|
| Progression Free Survival (PFS) as Assessed by the IRC | NA (NA to NA) | NA (NA to NA) |
Estimated percentage of participants who were event-free based on Kaplan-Meier method
| Percentage of Participants | Arm A: Ibrutinib | Arm B: Zanubrutinib |
|---|---|---|
| 12 Months | 87.2 (78.6 to 92.5) | 89.7 (81.7 to 94.3) |
| 18 Months | 83.8 (74.5 to 89.9) | 85.0 (75.2 to 91.2) |
PFS as assessed by the Investigator, defined as time from randomization to the first documentation of progression (per modified IWWM criteria) or death, whichever occurs first.
| Months | Arm A: Ibrutinib | Arm B: Zanubrutinib |
|---|---|---|
| PFS as Assessed by the Investigator | NA (54.4 to NA) | NA (NA to NA) |
Percentage of participants who were event-free based on Kaplan-Meier method.
| Percentage of Participants | Arm A: Ibrutinib | Arm B: Zanubrutinib |
|---|---|---|
| 24 Months | 80.6 (70.9 to 87.3) | 88.5 (80.2 to 93.5) |
| 36 Months | 74.8 (64.5 to 82.5) | 78.3 (68.4 to 85.5) |
| 48 Months | 67.3 (56.3 to 76.1) | 78.3 (68.4 to 85.5) |
| Percentage of Participants | Arm A: Ibrutinib | Arm B: Zanubrutinib |
|---|---|---|
| Percentage of Participants With Resolution of All Treatment-precipitating Symptoms | 78.6 | 79.2 |
Anti-Lymphoma Effect is defined as any reduction in bone marrow involvement by lymphoplasmacytoid lymphocytes and/or size of lymphadenopathy and/or splenomegaly by CT scan, at any time during the course of study treatment.
| Percentage of Participants | Arm A: Ibrutinib | Arm B: Zanubrutinib |
|---|---|---|
| Percentage of Participants With an Anti-Lymphoma Effect | 84.2 | 78.8 |
| Number of Participants | Arm A: Ibrutinib | Arm B: Zanubrutinib |
|---|---|---|
| Participants with At Least 1 TEAE | 98 | 101 |
| Participants with SAEs | 50 | 59 |
Collected over up to approximately 5 years and 5 months. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Ibrutinib | 19/99 (19.2%) | 50/98 (51%) | 96/98 (98%) |
| Arm B: Zanubrutinib | 14/102 (13.7%) | 59/101 (58.4%) | 99/101 (98%) |
| Event | Arm A: Ibrutinib | Arm B: Zanubrutinib |
|---|---|---|
| PneumoniaInfections and infestations | 14/98 | 2/101 |
| Atrial fibrillationCardiac disorders | 5/98 | 2/101 |
| SepsisInfections and infestations | 4/98 | 3/101 |
| PyrexiaGeneral disorders | 3/98 | 4/101 |
| Acute myocardial infarctionCardiac disorders | 3/98 | 2/101 |
| PericarditisCardiac disorders | 3/98 | 0/101 |
| Bladder transitional cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/98 | 0/101 |
| SyncopeNervous system disorders | 3/98 | 3/101 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/98 | 3/101 |
| NeutropeniaBlood and lymphatic system disorders | 0/98 | 3/101 |
| Event | Arm A: Ibrutinib | Arm B: Zanubrutinib |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 36/98 | 23/101 |
| Upper respiratory tract infectionInfections and infestations | 31/98 | 33/101 |
| NeutropeniaBlood and lymphatic system disorders | 16/98 | 29/101 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 28/98 | 12/101 |
| ContusionInjury, poisoning and procedural complications | 27/98 | 19/101 |
| FatigueGeneral disorders | 19/98 | 26/101 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 24/98 | 24/101 |
| HypertensionVascular disorders | 24/98 | 16/101 |
| AnaemiaBlood and lymphatic system disorders | 22/98 | 18/101 |
| Oedema peripheralGeneral disorders | 22/98 | 19/101 |
Intent to Treat (ITT) Analysis Set: Includes all randomized participants assigned to an arm.
| Age, Continuous(years) | Arm A: Ibrutinib | Arm B: Zanubrutinib | Total |
|---|---|---|---|
| Mean | 69.9 ± 8.58 | 69.2 ± 10.26 | 69.5 ± 9.46 |
| Sex: Female, Male(Participants) | Arm A: Ibrutinib | Arm B: Zanubrutinib | Total |
|---|---|---|---|
| Female | 34 | 33 | 67 |
| Male | 65 | 69 | 134 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Ibrutinib | Arm B: Zanubrutinib | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 4 | 8 |
| Not Hispanic or Latino | 91 | 82 | 173 |
| Unknown or Not Reported | 4 | 16 | 20 |
| Race (NIH/OMB)(Participants) | Arm A: Ibrutinib | Arm B: Zanubrutinib | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 4 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 94 | 88 | 182 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 10 | 15 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Jan 2017 to primary completion in Jun 2022, 64 months.
Results were first posted in Jun 2023, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibrutinib
Waldenstrom Macroglobulinemia →